GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Sloan Ratio %

Eargo (EAR) Sloan Ratio % : -46.24% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Eargo Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Eargo's Sloan Ratio for the quarter that ended in Sep. 2023 was -46.24%.

Warning Sign:

When sloan ratio (-28.09)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Sep. 2023, Eargo has a Sloan Ratio of -46.24%, indicating earnings are more likely to be made up of accruals.


Eargo Sloan Ratio % Historical Data

The historical data trend for Eargo's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eargo Sloan Ratio % Chart

Eargo Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial -6.94 -5.56 -3.75 -32.30 -28.09

Eargo Quarterly Data
Dec17 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.62 -28.09 -24.63 -75.22 -46.24

Competitive Comparison of Eargo's Sloan Ratio %

For the Medical Devices subindustry, Eargo's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eargo's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Eargo's Sloan Ratio % falls into.



Eargo Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Eargo's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(-157.487--117.304
--3.087)/132.078
=-28.09%

Eargo's Sloan Ratio for the quarter that ended in Sep. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2023 )
=(-108.173--75.369
--0.548)/69.753
=-46.24%

Eargo's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was -43.771 (Dec. 2022 ) + -21.922 (Mar. 2023 ) + -25.152 (Jun. 2023 ) + -17.328 (Sep. 2023 ) = $-108.17 Mil.
Eargo's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 was -20.442 (Dec. 2022 ) + -21.33 (Mar. 2023 ) + -18.86 (Jun. 2023 ) + -14.737 (Sep. 2023 ) = $-75.37 Mil.
Eargo's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 was -0.26 (Dec. 2022 ) + -0.132 (Mar. 2023 ) + -0.137 (Jun. 2023 ) + -0.019 (Sep. 2023 ) = $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eargo  (NAS:EAR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2023, Eargo has a Sloan Ratio of -46.24%, indicating earnings are more likely to be made up of accruals.


Eargo Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Eargo's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eargo (EAR) Business Description

Traded in Other Exchanges
N/A
Address
2665 North First Street, Suite 300, San Jose, CA, USA, 95134
Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.
Executives
Mark Thorpe officer: Chief Accounting Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie officer: Chief Operating Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis officer: Chief Financial Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen director, officer: President and CEO C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu director 411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson director C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo director 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB